Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PF-06873600 is a selective and orally bioavailable cyclin-dependent kinase (CDK) inhibitor(CDK2, CDK4 and CDK6 with Ki of 0.09 nM, 0.13 nM and 0.16 nM, respectively), has potential antineoplastic activity.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 113.00 | |
5 mg | In stock | $ 282.00 | |
10 mg | In stock | $ 448.00 | |
25 mg | In stock | $ 847.00 | |
50 mg | In stock | $ 1,130.00 | |
100 mg | In stock | $ 1,530.00 | |
500 mg | In stock | $ 2,970.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 349.00 |
Description | PF-06873600 is a selective and orally bioavailable cyclin-dependent kinase (CDK) inhibitor(CDK2, CDK4 and CDK6 with Ki of 0.09 nM, 0.13 nM and 0.16 nM, respectively), has potential antineoplastic activity. |
Targets&IC50 | CDK4:0.13 nM (Ki), CDK2:0.09 nM (Ki), CDK6:0.16 nM (Ki) |
In vitro | PF-06873600 selectively targets, binds to and inhibits the activity of CDKs.?Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation.?CDKs, ATP-dependent serine/threonine kinases that are important regulators of cell cycle progression and cellular proliferation, are frequently overexpressed in tumor cells. |
Molecular Weight | 471.52 |
Formula | C20H27F2N5O4S |
CAS No. | 2185857-97-8 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 83.33 mg/mL (176.73 mM), sonification is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PF-06873600 2185857-97-8 Cell Cycle/Checkpoint CDK PF 06873600 PF06873600 inhibitor inhibit